Abstract
Thilini N. Padeniya, Ben B. Hui, Nicolas Rebuli, David G. Regan, James G. Wood, Kate L. Seib
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Unresolved referenced work
Kept as external metadata until matched
Unresolved referenced work
Kept as external metadata until matched
Sexually transmitted diseases enhance HIV transmission: no longer a hypothesis.
10.1016/s0140-6736(98)90002-2 · 1998
HIV incidence among men with and those without sexually transmitted rectal infections: estimates from matching against an HIV case registry.
10.1093/cid/cit437 · 2013
Unresolved referenced work
Kept as external metadata until matched
The interrelation of demographic and geospatial risk factors between four common sexually transmitted diseases.
10.1136/sti.2004.009431 · 2005
Does core area theory apply to sexually transmitted diseases in rural environments?
10.1097/olq.0b013e3182762524 · 2013
Unresolved referenced work
Kept as external metadata until matched
Unresolved referenced work
Kept as external metadata until matched
Vaccine value profile for Neisseria gonorrhoeae.
10.1016/j.vaccine.2023.01.053 · 2024
Gonococcal vaccines: public health value and preferred product characteristics; report of a WHO global stakeholder consultation, January 2019.
10.1016/j.vaccine.2020.02.073 · 2020
Neisseria gonorrhoeae vaccine development: hope on the horizon?
10.1097/qco.0000000000000450 · 2018
Effectiveness of a group B outer membrane vesicle meningococcal vaccine against gonorrhoea in New Zealand: a retrospective case-control study.
10.1016/s0140-6736(17)31449-6 · 2017
Effectiveness of a serogroup B meningococcal vaccine against gonorrhea: a retrospective study.
10.1016/j.vaccine.2024.126312 · 2024
Long-term 4CMenB vaccine effectiveness against gonococcal infection at four years post-program implementation: observational case-control study.
10.1093/ofid/ofae726 · 2025
4CMenB sustained vaccine effectiveness against invasive meningococcal B disease and gonorrhoea at three years post programme implementation.
10.1016/j.jinf.2023.05.021 · 2023
Effectiveness and impact of the 4CMenB vaccine against invasive serogroup B meningococcal disease and gonorrhoea in an infant, child, and adolescent programme: an observational cohort and case-control study.
10.1016/s1473-3099(21)00754-4 · 2022
Meningococcus B vaccination effectiveness against Neisseria gonorrhoeae infection in people living with HIV: a case-control study.
10.1097/olq.0000000000001771 · 2023
Prevention of Neisseria gonorrhoeae with meningococcal B vaccine: a matched cohort study in Southern California.
10.1093/cid/ciac436 · 2023
Possible impact of wide-scale vaccination against serogroup B Neisseria meningitidis on gonorrhea incidence rates in one region of Quebec, Canada.
10.1093/ofid/ofx180.002 · 2017
Association of group B meningococcal vaccine receipt with reduced gonorrhea incidence among university students.
10.1001/jamanetworkopen.2023.31742 · 2023
Effectiveness of a serogroup B outer membrane vesicle meningococcal vaccine against gonorrhoea: a retrospective observational study.
10.1016/s1473-3099(21)00812-4 · 2022
Meningococcal B vaccine to prevent Neisseria gonorrhoeae infection.
10.1056/nejmoa2516739 · 2026
Efficacy of the meningococcal vaccine against Neisseria gonorrhoeae: a randomised clinical trial (MenGO).
10.1038/s41541-026-01422-y · 2026
Doxycycline prophylaxis and meningococcal group B vaccine to prevent bacterial sexually transmitted infections in France (ANRS 174 DOXYVAC): a multicentre, open-label, randomised trial with a 2 x 2 factorial design.
10.1016/s1473-3099(24)00236-6 · 2024
Review of mathematical models of Neisseria gonorrhoeae vaccine impact: implications for vaccine development.
10.1016/j.vaccine.2024.03.068 · 2024
Unresolved referenced work
Kept as external metadata until matched
Incidence of curable sexually transmissible infections among adolescents and young adults in remote Australian Aboriginal communities: analysis of longitudinal clinical service data.
10.1136/sextrans-2014-051617 · 2015
Unresolved referenced work
Kept as external metadata until matched
Australian gonococcal surveillance programme annual report, 2024.
10.33321/cdi.2025.49.056 · 2025
Unresolved referenced work
Kept as external metadata until matched
The potential impact of a vaccine on Neisseria gonorrhoeae prevalence among heterosexuals living in a high prevalence setting.
10.1016/j.vaccine.2023.07.048 · 2023
Unresolved referenced work
Kept as external metadata until matched
Unresolved referenced work
Kept as external metadata until matched
Unresolved referenced work
Kept as external metadata until matched
Unresolved referenced work
Kept as external metadata until matched
Vaccine effectiveness and impact of meningococcal vaccines against gonococcal infections: a systematic review and meta-analysis.
10.1016/j.jinf.2024.106225 · 2024
An observational study to assess the effectiveness of 4CMenB against meningococcal disease and carriage and gonorrhea in adolescents in the Northern Territory, Australia—study protocol.
10.3390/vaccines10020309 · 2022
Comprehensive observational study evaluating the enduring effectiveness of 4CMenB, the meningococcal B vaccine against gonococcal infections in the Northern Territory and South Australia, Australia: study protocol.
10.1136/bmjopen-2023-079144 · 2024
Population movement can sustain STI prevalence in remote Australian indigenous communities.
10.1186/1471-2334-13-188 · 2013
No additional external references are available.